Are We Ready for Multiple Switches Between Reference Products and Biosimilars?

Abstract

HIGHLIGHTS• The most crucial benefit of biosimilars is that they bring more significant cost reduction and increase access to advanced therapies.• For this to occur, it is imperative not only to use biosimilars in naïve patients but also to switch to biosimilars in those patients who have started therapy with reference biologics.• So far, studies have demonstrated effectiveness and safety of single switch between a reference product and a biosimilar.• The purpose of this manuscript is to discuss whether scientific evidence is enough to support multiple switches of biologics and biosimilars in IBD patients.